This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Company News for Aug 8, 2019
by Zacks Equity Research
Companies in the news are: DIS, CVS, CPRI and ODP
CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance
by Zacks Equity Research
CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.
U.S. Stock Index Futures Move Lower
by Zacks Equity Research
U.S. stock index futures moved lower
Stock Futures Fall as Trade Worries Spook Wall Street
by Zacks Equity Research
U.S. stock index futures moved lower ahead of trading on Wednesday after rising trade tensions led to concerns that a global economic slowdown was likely.
CVS Health (CVS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 11.18% and 1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Outlook for Health Insurance Industry Looks Sanguine
by Sapna Bagaria
Consolidation, increasing senior population, technological advancements and development of supplementary healthcare businesses poise the health insurance industry for secular growth.
Buy CVS Health (CVS) Ahead of Q2 Earnings?
by Christopher Vargas
CVS Health (CVS) will be reporting their second quarter before the opening bell on Wednesday.
Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?
by Zacks Equity Research
Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.
Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
by Zacks Equity Research
Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.
3 Retail Stocks Likely to Stand Tall This Earnings Season
by Zacks Equity Research
Retailers are making prudent investments to strengthen digital ecosystem and bolster shipping and delivery capabilities. While these drive sales, they entail high costs. Margins remain one of the key areas to watch.
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $56.26, marking a +1.3% move from the previous day.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DVP
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $55.47, marking a -0.84% move from the previous day.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $57.44, marking a -0.19% move from the previous day.
ETFs to Shine as Trump Tosses Drug Rebate Curb Plan
by Sweta Jaiswal, FRM
We study the impact of Trump's dropping of the proposed drug rebate rule on some health ETFs with exposure to pharmacy benefit managers and healthcare insurers.
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Stock Market News for Jul 12, 2019
by Zacks Equity Research
The Dow and S&P 500 closed at record highs on Thursday riding a rally among healthcare shares and Fed???s indication of an easier monetary policy.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Can CVS Health (CVS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $54.83 in the latest trading session, marking a -0.87% move from the prior day.
CVS Health Banks on Aetna Prospects, Omnicare May Disappoint
by Zacks Equity Research
CVS Health's (CVS) Aetna integration synergies bode well for the stock.
Here's Why CVS Health (CVS) Should Be in Your Portfolio
by Zacks Equity Research
Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.
Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More
by Kalyan Nandy
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Coca-Cola (KO) and Amgen (AMGN).